Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336141 · ClinicalTrials.gov registry record · Phase 1
Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00336141 is a Phase 1 study that has completed, run by University of Southern California. The registered enrollment target is 10 participants.
The verdict
NCT00336141, a Phase 1 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This protocol will investigate the use of vorinostat (suberoylanilide hydroxamic acid - SAHA) in combination with infusional 5-FU and leucovorin for the treatment of metastatic colorectal cancer patients who have failed standard 5FU regimens.
Interventions
- DRUG Suberoylanilide hydroxamic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00336141
The ClinicalTrials.gov registry entry for NCT00336141 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Suberoylanilide hydroxamic acid is the first listed.
NCT00336141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00336141 about?
NCT00336141 is a clinical study titled "Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer". This protocol will investigate the use of vorinostat (suberoylanilide hydroxamic acid - SAHA) in combination with infusional 5-FU and leucovorin for the treatment of metastatic colorectal cancer patients who have failed standard 5FU regimens.
What is the current status of trial NCT00336141?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2006-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00336141?
The interventions under investigation include: Suberoylanilide hydroxamic acid (DRUG).
Who is sponsoring clinical trial NCT00336141?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.